middle.news
Acrux Unveils 449% Growth in Generics Licensing and New R&D Focus at 2025 AGM
8:45am on Tuesday 25th of November, 2025 AEDT
•
Healthcare
Read Story
Acrux Unveils 449% Growth in Generics Licensing and New R&D Focus at 2025 AGM
8:45am on Tuesday 25th of November, 2025 AEDT
Key Points
Generics licensing revenue projected to increase 449% year-on-year in FY26
Strategic review underway to balance capital between generics and new R&D applications
FDA and international regulatory pathways highlighted for market expansion
Experienced leadership with CEO John Warmbrunn appointed in June 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE